Aer Therapeutics
Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel inhaled treatments for muco-obstructive lung diseases, focusing initially on COPD and expanding to other conditions like asthma, cystic fibrosis, and bronchiectasis. Their mission is to advance the treatment paradigm for mucus-mediated lung diseases through innovative therapies such as AER-01, a mucolytic designed to liquify mucus plugs in the lungs.
Industries
Nr. of Employees
small (1-50)
Aer Therapeutics
400 W North Street, Suite 112, Raleigh NC 27603
Products
Inhaled thiol-modified carbohydrate mucolytic clinical candidate
A clinical-stage small-molecule mucolytic designed to cleave mucin disulfide bonds and liquefy airway mucus plugs, formulated for nebulizer and dry powder inhaler delivery.
Inhaled thiol-modified carbohydrate mucolytic clinical candidate
A clinical-stage small-molecule mucolytic designed to cleave mucin disulfide bonds and liquefy airway mucus plugs, formulated for nebulizer and dry powder inhaler delivery.
Services
Design and operational execution of early-phase clinical studies for inhaled mucolytic candidates, including patient selection using imaging biomarkers.
Oversight of drug substance manufacturing, process and analytical development, and production of clinical trial API through external manufacturing partners.
Development and application of CT-based mucus plug scoring systems to identify patients with high mucus burden and to monitor therapeutic effects.
Design and operational execution of early-phase clinical studies for inhaled mucolytic candidates, including patient selection using imaging biomarkers.
Oversight of drug substance manufacturing, process and analytical development, and production of clinical trial API through external manufacturing partners.
Development and application of CT-based mucus plug scoring systems to identify patients with high mucus burden and to monitor therapeutic effects.
Expertise Areas
- Inhaled drug development
- Mucolytic therapeutic development
- Preclinical translational research
- CT-based imaging biomarkers for lungs
Key Technologies
- Thiol-based disulfide bond reduction chemistry
- Inhalation delivery (nebulizer and dry powder)
- Quantitative CT lung imaging and scoring
- Preclinical translational models
News & Updates
Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners. Proceeds to advance AER-01 into the clinic for treatment of COPD; unique targeted approach to treating patients affected by mucus plugs.
Reference: Addante A et al., A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J 2023; in press (https://doi.org/10.1183/13993003.02022-2022).
Editorial by: Burton F. Dickey and Christopher M. Evans Eur. Respir J 2023; 61: 2300619
Diaz A, Mucus plugs occluding COPD airways: A Review of their clinical impact. The 2023 International Workshop on Pulmonary Imaging; Philadelphia, PA, February 23 – 25, 2023
Reference: Dunican EM et al., Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers. Am J Respir Crit Care Med; Vol 203, Iss 8, pp 957–968, Apr 15, 2021
Reference: Okajima Y et al., Luminal plugging on chest CT scan, association with lung function, quality of life, and COPD clinical phenotypes. CHEST; 158(1):121-130, 2020
Supported by premier life science industry investors Canaan, OrbiMed, and Hatteras Venture Partners. Proceeds to advance AER-01 into the clinic for treatment of COPD; unique targeted approach to treating patients affected by mucus plugs.
Reference: Addante A et al., A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J 2023; in press (https://doi.org/10.1183/13993003.02022-2022).
Editorial by: Burton F. Dickey and Christopher M. Evans Eur. Respir J 2023; 61: 2300619
Diaz A, Mucus plugs occluding COPD airways: A Review of their clinical impact. The 2023 International Workshop on Pulmonary Imaging; Philadelphia, PA, February 23 – 25, 2023
Reference: Dunican EM et al., Mucus plugs and emphysema in the pathophysiology of airflow obstruction and hypoxemia in smokers. Am J Respir Crit Care Med; Vol 203, Iss 8, pp 957–968, Apr 15, 2021
Reference: Okajima Y et al., Luminal plugging on chest CT scan, association with lung function, quality of life, and COPD clinical phenotypes. CHEST; 158(1):121-130, 2020